Percutaneous catheter-based transluminal renal nerve ablation (RNA) by delivery of radiofrequency energy
constitutes a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to
the kidney and the sensory afferent signals to the central nervous system represent the targets of RNA. In this review we
summarize current recommendations for appropriate patient selection for RNA and multimodal strategies in order to
optimize pharmacological treatment for resistant hypertension. The safety and efficacy of the RNA based on published
trials are also presented. Furthermore, a detailed description of the periprocedural management, the methodology of the
RNA procedure and appropriate follow-up are provided. In conclusion, in order to improve the overall clinical outcome
and achieve optimal management of resistant hypertensive patients before and after the RNA, experienced and certified
centers are of major importance.
Keywords: Invasive procedure, renal denervation, resistant hypertension.
Rights & PermissionsPrintExport